Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma (Alternative)
A Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib in Combination With GA 101 in Patients With Previously Untreated Follicular Lymphoma and a High Tumor Burden
Sponsor: Hoffmann-La Roche
This PHASE2 trial investigates Indolent Non-Hodgkin Lymphoma and is currently ongoing. Hoffmann-La Roche leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jun 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2021 — Jun 2023 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Oct 2018 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Apr 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
- Janssen-Cilag G.m.b.H
- Ludwig-Maximilians - University of Munich
For direct contact, visit the study record on ClinicalTrials.gov .